Core IM | Internal Medicine Podcast
#136 How Did Diabetes Medications Become Obesity Meds? Beyond Journal Club on SURMOUNT-1 Trial
Episode guests
Podcast summary created with Snipd AI
Quick takeaways
- Terzepitide, a once-weekly injectable drug, has been found to be highly effective in promoting weight loss, with patients losing an average of 20% of their body weight over a year compared to only 3% for those on a placebo.
- Incretin mimetics like Terzepitide target the incretin system, regulating appetite and glucose levels in the body, and not only promote weight loss but also improve metabolic parameters such as blood pressure, cholesterol levels, and insulin resistance.
Deep dives
Terzepitide: A Revolutionary Weight Loss Drug
Terzepitide, a once-weekly injectable drug, has been found to be highly effective in promoting weight loss. In a trial called Sir Mount One, patients who received 10 or 15 milligrams of Terzepitide lost an average of 20% of their body weight over the course of a year, compared to only 3% for those on a placebo. The trial included middle-aged individuals who were overweight and had weight-related complications like hypertension and dyslipidemia. Along with significant weight loss, patients experienced improvements in waist circumference, blood pressure, cholesterol levels, and insulin resistance. Additionally, Terzepitide showed better tolerance and fewer gastrointestinal side effects compared to other weight loss drugs. This breakthrough drug provides hope for individuals struggling with obesity and its related health issues.
Remember Everything You Learn from Podcasts
